94 related articles for article (PubMed ID: 7945729)
1. Cytotoxic activity of two new lipophilic steroid nitrogen carbamates incorporated into low-density lipoprotein.
Lundberg B
Anticancer Drug Des; 1994 Oct; 9(5):471-6. PubMed ID: 7945729
[TBL] [Abstract][Full Text] [Related]
2. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway.
Lundberg B
Cancer Res; 1987 Aug; 47(15):4105-8. PubMed ID: 3607752
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells.
Masquelier M; Lundberg B; Peterson C; Vitols S
Leuk Res; 2006 Feb; 30(2):136-44. PubMed ID: 16085310
[TBL] [Abstract][Full Text] [Related]
4. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex.
Vitols S; Söderberg-Reid K; Masquelier M; Sjöström B; Peterson C
Br J Cancer; 1990 Nov; 62(5):724-9. PubMed ID: 2245164
[TBL] [Abstract][Full Text] [Related]
5. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells.
Kader A; Pater A
J Control Release; 2002 Apr; 80(1-3):29-44. PubMed ID: 11943385
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.
Masquelier M; Vitols S; Peterson C
Cancer Res; 1986 Aug; 46(8):3842-7. PubMed ID: 3731059
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
Bacherikov VA; Chou TC; Dong HJ; Chen CH; Lin YW; Tsai TJ; Su TL
Bioorg Med Chem Lett; 2004 Sep; 14(18):4719-22. PubMed ID: 15324894
[TBL] [Abstract][Full Text] [Related]
8. Selective delivery of cytotoxic compounds to cells by the LDL pathway.
Firestone RA; Pisano JM; Falck JR; McPhaul MM; Krieger M
J Med Chem; 1984 Aug; 27(8):1037-43. PubMed ID: 6086924
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells.
Lestavel-Delattre S; Martin-Nizard F; Clavey V; Testard P; Favre G; Doualin G; Houssaini HS; Bard JM; Duriez P; Delbart C
Cancer Res; 1992 Jul; 52(13):3629-35. PubMed ID: 1617635
[TBL] [Abstract][Full Text] [Related]
10. Use of steroids as carriers of cytotoxic agents in breast cancer: estrogens linked with nitrogen mustard groups [proceedings].
Lippman M
Cancer Treat Rep; 1978 Aug; 62(8):1259-60. PubMed ID: 688264
[No Abstract] [Full Text] [Related]
11. [Targeting of tumor cells by low density lipoproteins: principle and use of ellipticin derivatives].
Favre G
C R Seances Soc Biol Fil; 1992; 186(1-2):73-87. PubMed ID: 1450992
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells.
Firestone RA
Bioconjug Chem; 1994; 5(2):105-13. PubMed ID: 8031872
[No Abstract] [Full Text] [Related]
13. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood.
Masquelier M; Vitols S; Pålsson M; Mårs U; Larsson BS; Peterson CO
J Drug Target; 2000; 8(3):155-64. PubMed ID: 10938525
[TBL] [Abstract][Full Text] [Related]
14. Uptake of low-density lipoprotein by malignant cells--possible therapeutic applications.
Vitols S
Cancer Cells; 1991 Dec; 3(12):488-95. PubMed ID: 1840290
[TBL] [Abstract][Full Text] [Related]
15. ZR-75-1 breast cancer cells generate nonconjugated steroids from low density lipoprotein-incorporated lipoidal dehydroepiandrosterone.
Roy R; Bélanger A
Endocrinology; 1993 Aug; 133(2):683-9. PubMed ID: 8344206
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity and gene expression profiles of novel synthesized steroid derivatives as chemotherapeutic anti-breast cancer agents.
Elmegeed GA; Khalil WK; Mohareb RM; Ahmed HH; Abd-Elhalim MM; Elsayed GH
Bioorg Med Chem; 2011 Nov; 19(22):6860-72. PubMed ID: 22000946
[TBL] [Abstract][Full Text] [Related]
17. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.
Koller-Lucae SK; Schott H; Schwendener RA
Br J Cancer; 1999 Jul; 80(10):1542-9. PubMed ID: 10408395
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoclinical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate.
Müntzing J; Shukla SK; Chu TM; Mittelman A; Murphy GP
Invest Urol; 1974 Jul; 12(1):65-8. PubMed ID: 4835492
[No Abstract] [Full Text] [Related]
19. Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein.
de Smidt PC; van Berkel TJ
Cancer Res; 1990 Dec; 50(23):7476-82. PubMed ID: 2147578
[TBL] [Abstract][Full Text] [Related]
20. Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins.
Ware DC; Palmer HR; Pruijn FB; Anderson RF; Brothers PJ; Denny WA; Wilson WR
Anticancer Drug Des; 1998 Mar; 13(2):81-103. PubMed ID: 9524553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
